EP2879670A4 - Compositions antibactériennes et procédés antibactériens - Google Patents

Compositions antibactériennes et procédés antibactériens

Info

Publication number
EP2879670A4
EP2879670A4 EP13826328.0A EP13826328A EP2879670A4 EP 2879670 A4 EP2879670 A4 EP 2879670A4 EP 13826328 A EP13826328 A EP 13826328A EP 2879670 A4 EP2879670 A4 EP 2879670A4
Authority
EP
European Patent Office
Prior art keywords
methods
antibacterial compositions
antibacterial
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13826328.0A
Other languages
German (de)
English (en)
Other versions
EP2879670A1 (fr
Inventor
Alena Fedarovich
Christopher Davies
Yuri Karl Peterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical University of South Carolina Foundation
Original Assignee
Medical University of South Carolina Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical University of South Carolina Foundation filed Critical Medical University of South Carolina Foundation
Publication of EP2879670A1 publication Critical patent/EP2879670A1/fr
Publication of EP2879670A4 publication Critical patent/EP2879670A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9446—Antibacterials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP13826328.0A 2012-08-01 2013-08-01 Compositions antibactériennes et procédés antibactériens Withdrawn EP2879670A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261678427P 2012-08-01 2012-08-01
PCT/US2013/053127 WO2014022613A1 (fr) 2012-08-01 2013-08-01 Compositions antibactériennes et procédés antibactériens

Publications (2)

Publication Number Publication Date
EP2879670A1 EP2879670A1 (fr) 2015-06-10
EP2879670A4 true EP2879670A4 (fr) 2016-03-02

Family

ID=50028521

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13826328.0A Withdrawn EP2879670A4 (fr) 2012-08-01 2013-08-01 Compositions antibactériennes et procédés antibactériens

Country Status (2)

Country Link
EP (1) EP2879670A4 (fr)
WO (1) WO2014022613A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016025932A1 (fr) * 2014-08-15 2016-02-18 Ptc Therapeutics, Inc. Composés antibactériens polycycliques substitués
WO2016025933A2 (fr) * 2014-08-15 2016-02-18 Ptc Therapeutics, Inc. Composes antibacteriens polycycliques substitues
WO2016039939A1 (fr) * 2014-09-09 2016-03-17 Ptc Therapeutics, Inc. Composés 2-pyridinone antibactériens à substitution bicyclique et tricyclique
WO2016039937A1 (fr) * 2014-09-09 2016-03-17 Ptc Therapeutics, Inc. Composés 2-pyridinone substitués bicycliques et tricycliques antibactériens
WO2016039938A1 (fr) * 2014-09-09 2016-03-17 Ptc Therapeutics, Inc. Composés 2-pyridinone polycycliques antibactériens
WO2016039936A2 (fr) * 2014-09-09 2016-03-17 Ptc Therapeutics, Inc. Composés 2-pyridinone substitués monocycliques antibactériens

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007041241A2 (fr) * 2005-09-30 2007-04-12 The Trustees Of Columbia University In The City Of New York Compositions et procedes permettant la detection des interactions ligand-recepteur
US20090203641A1 (en) * 2008-01-15 2009-08-13 Chi-Huey Wong Antibiotic compositions and related screening methods
WO2010129779A1 (fr) * 2009-05-07 2010-11-11 Biomerieux, Inc. Méthodes de détermination de la résistance antimicrobienne

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574017A (en) * 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
JP2007513055A (ja) * 2003-08-13 2007-05-24 オシエント ファーマシューティカルズ 抗菌性シクロアルキルテトラヒドロキノリン誘導体
AU2008327884B2 (en) * 2007-11-21 2013-01-24 Katholieke Universiteit Leuven, K.U. Leuven R & D Inhibitors of MALT1 proteolytic activity and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007041241A2 (fr) * 2005-09-30 2007-04-12 The Trustees Of Columbia University In The City Of New York Compositions et procedes permettant la detection des interactions ligand-recepteur
US20090203641A1 (en) * 2008-01-15 2009-08-13 Chi-Huey Wong Antibiotic compositions and related screening methods
WO2010129779A1 (fr) * 2009-05-07 2010-11-11 Biomerieux, Inc. Méthodes de détermination de la résistance antimicrobienne

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
A G BARBOUR: "Properties of penicillin-binding proteins in Neisseria gonorrhoeae.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 19, no. 2, 1 February 1981 (1981-02-01), US, pages 316 - 322, XP055243361, ISSN: 0066-4804, DOI: 10.1128/AAC.19.2.316 *
DAVID M. JAMESON ET AL: "Fluorescence Polarization/Anisotropy in Diagnostics and Imaging", CHEMICAL REVIEWS, vol. 110, no. 5, 12 May 2010 (2010-05-12), US, pages 2685 - 2708, XP055243358, ISSN: 0009-2665, DOI: 10.1021/cr900267p *
DAVID S SMITH ET AL: "Fluorescence polarization immunoassays and related methods for simple, high-throughput screening of small molecules", ANALYTICAL AND BIOANALYTICAL CHEMISTRY, SPRINGER, BERLIN, DE, vol. 391, no. 5, 10 February 2008 (2008-02-10), pages 1499 - 1507, XP019621293, ISSN: 1618-2650 *
KENNY C H ET AL: "Development of a fluorescence polarization assay to screen for inhibitors of the FtsZ/ZipA interaction", ANALYTICAL BIOCHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 323, no. 2, 15 December 2003 (2003-12-15), pages 224 - 233, XP004476342, ISSN: 0003-2697, DOI: 10.1016/J.AB.2003.08.033 *
OWICKI J C: "FLUORESCENCE POLARIZATION AND ANISOTROPY IN HIGH THROUGPUT SCREENING: PERSPECTIVES AND PRIMER", JOURNAL OF BIOMOLECULAR SCREENING, SAGE; LIEBERT, US, vol. 5, no. 5, 1 October 2000 (2000-10-01), pages 297 - 306, XP009007612, ISSN: 1087-0571, DOI: 10.1177/108705710000500501 *
See also references of WO2014022613A1 *
STEVEN R INGLIS ET AL: "A boronic-acid-based probe for fluorescence polarization assays with penicillin binding proteins and -lactamases", ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS INC, NEW YORK, vol. 420, no. 1, 19 August 2011 (2011-08-19), pages 41 - 47, XP028323069, ISSN: 0003-2697, [retrieved on 20110826], DOI: 10.1016/J.AB.2011.08.036 *
ZHANG R ET AL: "Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction", ANALYTICAL BIOCHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 331, no. 1, 1 August 2004 (2004-08-01), pages 138 - 146, XP004520205, ISSN: 0003-2697, DOI: 10.1016/J.AB.2004.03.009 *
ZHAO GENSHI ET AL: "BOCILLIN FL, a sensitive and commercially available reagent for detection of penicillin-binding proteins", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 43, no. 5, 1 May 1999 (1999-05-01), pages 1124 - 1128, XP002587010, ISSN: 0066-4804 *

Also Published As

Publication number Publication date
WO2014022613A1 (fr) 2014-02-06
EP2879670A1 (fr) 2015-06-10

Similar Documents

Publication Publication Date Title
EP2836212A4 (fr) Nouvelles compositions et nouveaux procédés
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
GB201217441D0 (en) Composition
HK1216250A1 (zh) &#39;- &#39;-羥基-二氫麥角胺化合物及組合物
GB201200707D0 (en) Composition
HK1212156A1 (en) Antimicrobial composition
EP2878295A4 (fr) Composition
GB201218954D0 (en) Composition
GB201315350D0 (en) Methods and compositions
ZA201502275B (en) Antibacterial compositions
EP2879670A4 (fr) Compositions antibactériennes et procédés antibactériens
GB201315347D0 (en) Methods and compositions
EP2874641A4 (fr) Compositions élevant le taux de glutathion et leurs utilisations
GB201219657D0 (en) Composition
GB201206035D0 (en) Composition
EP2837670A4 (fr) Composition contenant un fluorobiphényle
EP2910537A4 (fr) Composition d&#39;agent générant du gaz
EP2910538A4 (fr) Composition d&#39;agent générant du gaz
GB201209597D0 (en) Composition
GB201208133D0 (en) Composition
EP2838365A4 (fr) Compositions antimicrobiennes et leurs utilisations
GB201219383D0 (en) Composition
GB201218195D0 (en) Composition
ZA201408903B (en) Antimicrobial composition
HUE032878T2 (hu) Bõrvédõ és bõrkiegyensúlyozó készítmény

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150202

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160201

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4375 20060101ALI20160126BHEP

Ipc: A61K 31/132 20060101ALI20160126BHEP

Ipc: A61K 31/18 20060101ALI20160126BHEP

Ipc: A61K 31/4196 20060101ALI20160126BHEP

Ipc: A61K 31/341 20060101ALI20160126BHEP

Ipc: A61K 31/381 20060101ALI20160126BHEP

Ipc: A61K 31/473 20060101ALI20160126BHEP

Ipc: A61K 31/427 20060101ALI20160126BHEP

Ipc: A61K 31/404 20060101ALI20160126BHEP

Ipc: A61K 31/382 20060101ALI20160126BHEP

Ipc: A61K 31/515 20060101ALI20160126BHEP

Ipc: A61K 31/15 20060101ALI20160126BHEP

Ipc: A61K 31/136 20060101ALI20160126BHEP

Ipc: A61K 31/13 20060101AFI20160126BHEP

Ipc: A61K 31/12 20060101ALI20160126BHEP

Ipc: A61K 31/47 20060101ALI20160126BHEP

Ipc: C12Q 1/18 20060101ALI20160126BHEP

Ipc: G01N 33/94 20060101ALI20160126BHEP

Ipc: A61K 31/426 20060101ALI20160126BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170914

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180125